Home/Pipeline/DARC for Glaucoma

DARC for Glaucoma

Glaucoma

Exploratory Biomarker in Clinical StudiesActive

Key Facts

Indication

Glaucoma

Phase

Exploratory Biomarker in Clinical Studies

Status

Active

Company

Novai

About Novai

Novai is a private, clinical-stage UK MedTech company developing a novel diagnostic and biomarker platform called DARC. The technology detects apoptosing retinal cells in vivo, providing an early, objective measure of disease activity for conditions like glaucoma and age-related macular degeneration (AMD). Founded and led by renowned clinician-scientist Prof. Francesca Cordeiro, the company is positioning DARC as a tool to empower earlier patient intervention, guide clinician treatment decisions, and de-risk drug development for pharmaceutical partners. Novai appears to be in a pre-revenue, late-stage development phase, advancing its technology through clinical studies.

View full company profile

Therapeutic Areas

Ophthalmology Neurodegeneration

Other Glaucoma Drugs

Drug	Company	Phase	Status
PREZIA Glaucoma Implant	PolyActiva	Preclinical	Active
MIGS Device System	Micropoint Biotechnologies	Commercial	Market approved in China
INM-088	InMed Pharmaceuticals	Preclinical	Active
OT-401	Ocumension Therapeutics	Phase 2	Active
ANX007	Annexon Biosciences	Phase 2	Active
PER-001	Perfuse Therapeutics	Phase 2	Active
hOTX2	BrainEver	Discovery	Active
Glaucoma Treatment	BVI Medical	Commercial	Active
MediPrint Lens (Glaucoma)	MediPrint Ophthalmics	Phase 2b	Active
Glaucoma Program	Broadwing Bio	Pre-clinical	Active
MSC Exosomal Eye Serum	Vitti Labs	Pre-clinical	Active
BTQ1902	Betaliq	Phase 2	Active